Your session is about to expire
← Back to Search
9vHPV + COVID-19 Vaccines for HPV and Coronavirus Prevention
Study Summary
This trial is testing whether it is non-inferior to give two doses of the 9vHPV vaccine and two doses of the mRNA-1273 vaccine at the same time or if it is better to spread them out.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 614 Patients • NCT04313244Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of heart muscle or heart sac inflammation.You have already received an HPV vaccine or participated in an HPV vaccine study.You have had a serious allergic reaction in the past that needed medical attention.You have had your spleen removed through surgery.You have an allergy to any part of the vaccine.You or your child must be between 9 and 11 years of age.
- Group 1: Non-concomitant Group
- Group 2: Concomitant Group
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there specific requirements for volunteers in this research project?
"Eligible participants for this study must be between 9-11 years old and have a papillomavirus infection. Up to 400 individuals can take part in the clinical trial."
Has this medical experiment been conducted before?
"As of now, there are 70 active studies regarding the 9vHPV Vaccine in 295 cities across 46 countries. The very first clinical trial was sponsored by Merck Sharp & Dohme Corp. and took place in 2002. 12167 people participated in the Phase 3 drug approval process. In the 18 years since 2002, 128 trials have completed."
Is there room for new patients in this trial?
"Yes, this is an active recruitment. The clinical trial was posted on 3/28/2022 and was most recently edited on 10/28/2022. They are looking for 400 patients at 31 locations."
Is this the first time the 9vHPV Vaccine has been used in a clinical setting?
"Currently, there are 70 different 9vHPV Vaccine clinical trials underway with 29 of them in Phase 3. Most of these studies are happening in Miami, Florida, however, there are 878 total locations running trials for 9vHPV Vaccine."
How many slots are open for patients in this experiment?
"The sponsor, Merck Sharp & Dohme Corp., needs to enroll 400 eligible patients from different clinical trial sites in order to begin the study. These sites are located in Washington, D.C. and Little Rock, Arkansas."
Will this trial be accepting participants who are under the age of 40?
"According to the inclusion criteria, only patients aged 9 to 11 are eligible for this particular clinical trial. Out of the total 3077 clinical trials, 197 are for patients under 18 and 1080 are for patients over 65."
Can you tell me how many different research facilities are participating in this project?
"This trial has 31 recruiting sites, some of which are the Emerson Clinical Research Institute (Site 0021) in Washington, Preferred Research Partners Inc. (Site 0092) in Little Rock, and Cognitive Clinical Trials, LLC (Site 0054) in Phoenix."
Are there any risks associated with receiving the 9vHPV Vaccine?
"The 9vHPV Vaccine received a safety score of 3. This is due to the fact that it is a Phase 3 trial, indicating that there is both data supporting its efficacy and multiple rounds of data affirming its safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger